Hirai Keiji, Shimotashiro Masako, Okumura Toshiaki, Ookawara Susumu, Morishita Yoshiyuki
Division of Nephrology, First Department of Integrated Medicine, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Mizue Yuai Clinic, Tokyo, Japan.
Kidney Res Clin Pract. 2024 May;43(3):326-336. doi: 10.23876/j.krcp.23.121. Epub 2024 Feb 19.
We assessed the anti-SARS-CoV-2 spike antibody response to the third dose of BNT162b2 mRNA COVID-19 vaccine in Japanese hemodialysis patients and determined factors associated with the anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine.
Overall, 64 patients were enrolled in this single-center, prospective, longitudinal study. Anti-SARS-CoV-2 spike antibody titers were compared between hemodialysis patients and 18 healthcare workers. Multiple linear regression analysis was used to identify factors associated with the anti-SARS-CoV-2 spike antibody titer after the third vaccination.
There was no significant difference in anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination between hemodialysis patients and healthcare workers (18,500 [interquartile range, 11,000-34,500] vs. 11,500 [interquartile range, 7,918- 19,500], all values in AU/mL; p = 0.17). Uric acid (standard coefficient [β] = -0.203, p = 0.02), transferrin saturation (β = -0.269, p = 0.003), and log-anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.440, p < 0.001) correlated with the log-anti-SARS-CoV-2 spike antibody titer 4 weeks after the third vaccination. In contrast, only the log-anti-SARS-CoV-2 spike antibody titer 1 week before the third vaccination (β = 0.410, p < 0.001) correlated with the log- anti-SARS-CoV-2 spike antibody titer 12 weeks after the third vaccination.
The anti-SARS-CoV-2 spike antibody titer after the third dose of COVID-19 vaccine was comparable between hemodialysis patients and healthcare workers. Uric acid concentration, transferrin saturation, and anti-SARS-CoV-2 spike antibody titer before the third dose were associated with the anti-SARS-CoV-2 spike antibody titer after the third dose in Japanese hemodialysis patients.
我们评估了日本血液透析患者对第三剂BNT162b2 mRNA新冠疫苗的抗SARS-CoV-2刺突抗体反应，并确定了与第三剂新冠疫苗后抗SARS-CoV-2刺突抗体滴度相关的因素。
本单中心、前瞻性、纵向研究共纳入64例患者。比较了血液透析患者和18名医护人员的抗SARS-CoV-2刺突抗体滴度。采用多元线性回归分析确定与第三次接种后抗SARS-CoV-2刺突抗体滴度相关的因素。
血液透析患者和医护人员在第三次接种后4周的抗SARS-CoV-2刺突抗体滴度无显著差异（18,500[四分位间距，11,000 - 34,500]对11,500[四分位间距，7,918 - 19,500]，所有值单位为AU/mL；p = 0.17）。尿酸（标准系数[β]= -0.203，p = 0.02）、转铁蛋白饱和度（β = -0.269，p = 0.003）和第三次接种前1周的抗SARS-CoV-2刺突抗体滴度对数（β = 0.440，p < 0.001）与第三次接种后4周的抗SARS-CoV-2刺突抗体滴度对数相关。相比之下，只有第三次接种前1周的抗SARS-CoV-2刺突抗体滴度对数（β = 0.410，p < 0.001）与第三次接种后12周的抗SARS-CoV-2刺突抗体滴度对数相关。
血液透析患者和医护人员在第三剂新冠疫苗接种后的抗SARS-CoV-2刺突抗体滴度相当。在日本血液透析患者中，尿酸浓度、转铁蛋白饱和度和第三剂接种前的抗SARS-CoV-2刺突抗体滴度与第三剂接种后的抗SARS-CoV-2刺突抗体滴度相关。
